	US 12,215,158 B2
	CD1a antibody-expressing CAR T-cells for the treatment of CD1a-positive cancer
Pablo Menéndez Buján, Barcelona (ES); Diego Sanchez Martínez, Barcelona (ES); Clara Bueno Uroz, Barcelona (ES); Francisco Gutiérrez Agüera, Barcelona (ES); and Heleia Roca-Ho, Barcelona (ES)
Assigned to FUNDACÍON INSTITUTO DE INVESTIGACÍON CONTRA LA LEUCEMIA JOSEP CARRERAS (IJC), Barcelona (ES); INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANATS (ICREA), Barcelona (ES); and FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL (IGTP), Badalona (ES)
Appl. No. 17/430,705
Filed by FUNDACIÓN INSTITUTO DE INVESTIGACIÓN CONTRA LA LEUCEMIA JOSEP CARRERAS (IJC), Barcelona (ES); INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇ ̧ATS (ICREA), Barcelona (ES); and FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL (IGTP), Badalona (ES)
PCT Filed Feb. 13, 2020, PCT No. PCT/EP2020/053769 § 371(c)(1), (2) Date Aug. 12, 2021, PCT Pub. No. WO2020/165350, PCT Pub. Date Aug. 20, 2020.
Claims priority of application No. 19382104 (EP), filed on Feb. 14, 2019.
Prior Publication US 2022/0143085 A1, May 12, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 16/2833 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464429 (2023.05); A61P 35/00 (2018.01); C07K 14/705 (2013.01); C12N 5/0636 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05)]

17 Claims

1. A method of treating a CD 1a-positive cancer in a subject in need thereof, said method comprising administering to said subject a CD1a-negative allo-tolerant T cell comprising a nucleic acid encoding a chimeric antigen receptor (CAR) comprising:

(i) an extracellular domain comprising a CD 1a targeting-moiety, wherein the CD 1a targeting moiety is an antibody, scFv, Fab, or scFab comprising a VL domain and VH domain,

wherein said VL domain comprises LCDR1, LCDR2 and LCDR3 polypeptides and said VH domain comprises HCDR1, HCDR2 and HCDR3 polypeptides, and LCDR1 consists of QDINKY (SEQ ID NO: 1), LCDR2 consists of YTS, LCDR3 consists of LHYDNLPWT (SEQ ID NO: 3), HCDR1 consists of GYAFSTYT (SEQ ID NO: 4), HCDR2 consists of INPNSAST (SEQ ID NO: 5), and HCDR3 consists of ARGFYTMDY (SEQ ID NO: 6);

(ii) a transmembrane domain; and

(iii) an intracellular signaling domain.